Xiaohua Ye

Xiaohua Ye

Auto-generated profile, based on publicly available information

Xiaohua Ye

Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Vaccine
Verified
Journal Article
Closed access
Zhiqiang KuZhiqiang Ku
Zhiqiang Ku
QLQingwei Liu
Qingwei Liu
XYXiaohua Ye
Xiaohua Ye
YCYicun Cai
Yicun Cai
XWXiaoli Wang
Xiaoli Wang
ZHZhong Huang
Zhong Huang

1 May 2015 in Vaccine
Verified
Journal Article
Closed access
CZChao Zhang
Chao Zhang
Zhiqiang KuZhiqiang Ku
Zhiqiang Ku
QLQingwei Liu
Qingwei Liu
XWXiaoli Wang
Xiaoli Wang
TCTan Chen
Tan Chen
ZHZhong Huang
Zhong Huang

1 January 2014 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
XYXiaohua Ye
Xiaohua Ye
Zhiqiang KuZhiqiang Ku
Zhiqiang Ku
QLQingwei Liu
Qingwei Liu
XWXiaoli Wang
Xiaoli Wang
JSJinping Shi
Jinping Shi
ZHZhong Huang
Zhong Huang
Enterovirus 71 (EV71) is a major causative agent of hand, food, and mouth disease, which frequently occurs in young children. Since there are 11 subgenotypes (A, B1 to B5, and C1 to C5) within EV71, an EV71 vaccine capable of protecting against all of these subgenotypes is desirable. We report here the vaccine potential and protective mechanism of two chimeric virus-like particles (VLPs) presenting conserved neutralizing epitopes of EV71. We show that fusions of hepatitis B core antigen (HBc) with the SP55 or SP70 epitope of EV71, designated HBcSP55 and HBcSP70, respectively, can be rapidly generated and self-assembled into VLPs with the epitopes displayed on the surface. Immunization with the chimeric VLPs induced carrier- and epitope-specific antibody responses in mice. Anti-HBcSP55 and anti-HBcSP70 sera, but not anti-HBc sera, were able to neutralize in vitro multiple genotypes and strains of EV71. Importantly, passive immunization with anti-HBcSP55 or anti-HBcSP70 sera protected neonatal mice against lethal EV71 infections. Interestingly, anti-HBcSP70 sera could inhibit EV71 attachment to susceptible cells, whereas anti-HBcSP55 sera could not. However, both antisera were able to neutralize EV71 infection in vitro at the postattachment stage. The divergent mechanism of neutralization and protection conferred by anti-SP70 and anti-SP55 sera is in part attributed to their respective ability to bind authentic viral particles. Collectively, our study not only demonstrates that chimeric VLPs displaying the SP55 and SP70 epitopes are promising candidates for a broad-spectrum EV71 vaccine but also reveals distinct mechanisms of neutralization by the SP55- and SP70-targeted antibodies.

22 February 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Zhiqiang KuZhiqiang Ku
Zhiqiang Ku
XYXiaohua Ye
Xiaohua Ye
XHXulin Huang
Xulin Huang
YCYicun Cai
Yicun Cai
QLQingwei Liu
Qingwei Liu
ZHZhong Huang
Zhong Huang
Enterovirus 71 (EV71) is a major causative agent of hand, foot and mouth disease, which has been prevalent in Asia–Pacific regions, causing significant morbidity and mortality in young children. Antibodies elicited by experimental EV71 vaccines could neutralize infection in vitro and passively protect animal models from lethal challenge, indicating that neutralizing antibodies play an essential role in protection. However, how neutralizing antibodies inhibit infection in vitro remains unclear. In the present study, we explored the mechanisms of neutralization by antibodies against EV71 virus-like particles (VLPs). Recombinant VLPs of EV71 genotype C4 were produced in insect cells using baculovirus vectors. Immunization with the VLPs elicited a high-titer, EV71-specific antibody response in mice. Anti-VLP mouse sera potently neutralized EV71 infection in vitro. The neutralizing antibodies in the anti-VLP mouse sera were found to target mainly an extremely conserved epitope (FGEHKQEKDLEYGAC) located at the GH loop of the VP1 protein. The neutralizing anti-VLP antisera were able to inhibit virus binding to target cells efficiently. In addition, post-attachment treatment of virus-bound cells with the anti-VLP antisera also neutralized virus infection, although the antibody concentration required was higher than that of the pre-attachment treatment. Collectively, our findings represent a valuable addition to the understanding of mechanisms of EV71 neutralization and have strong implications for EV71 vaccine development.

18 May 2018 in Emerging Microbes & Infections
Verified
Journal Article
Open access
WZWei Zhang
Wei Zhang
WDWenlong Dai
Wenlong Dai
CZChao Zhang
Chao Zhang
YZYu Zhou
Yu Zhou
PXPei Xiong
Pei Xiong
ZHZhong Huang
Zhong Huang
Hand, foot, and mouth disease (HFMD) is an infectious disease that mainly affects infants and children, causing considerable morbidity and mortality worldwide. HFMD is commonly caused by enteroviru...

1 December 2015 in Journal of Virology
Verified
Journal Article
Open access
PDF file
Zhiqiang KuZhiqiang Ku
Zhiqiang Ku
XYXiaohua Ye
Xiaohua Ye
JSJinping Shi
Jinping Shi
XWXiaoli Wang
Xiaoli Wang
LQLIU Qingwei
LIU Qingwei
ZHZhong Huang
Zhong Huang
Antibodies play a critical role in immunity against enterovirus 71 (EV71). However, how EV71-specific antibodies neutralize infections remains poorly understood. Here we report the working mechanism for a group of three monoclonal antibodies (MAbs) that potently neutralize EV71. We found that these three MAbs (termed D5, H7, and C4, respectively) recognize the same conserved neutralizing epitope within the VP1 GH loop of EV71. Single MAbs in this group, exemplified by D5, could inhibit EV71 infection in cell cultures at both the pre- and postattachment stages in a cell type-independent manner. Specifically, MAb treatment resulted in the blockade of multiple steps of EV71 entry, including virus attachment, internalization, and subsequent uncoating and RNA release. Furthermore, we show that the D5 and C4 antibodies can interfere with EV71 binding to its key receptors, including heparan sulfate, SCARB2, and PSGL-1, thus providing a possible explanation for the observed multi-inhibitory function of the MAbs. Collectively, our study unravels the mechanism of neutralization by a unique group of anti-EV71 MAbs targeting the conserved VP1 GH loop. The findings should enhance our understanding of MAb-mediated immunity against enterovirus infections and accelerate the development of MAb-based anti-EV71 therapeutic drugs. IMPORTANCE Enterovirus 71 (EV71) is a major causative agent of hand, foot, and mouth disease (HFMD), which has caused significant morbidities and mortalities in young children. Neither a vaccine nor an antiviral drug is available. Neutralizing antibodies are major protective components in EV71 immunity. Here, we unraveled an unusual mechanism of EV71 neutralization by a group of three neutralizing monoclonal antibodies (MAbs). All of these MAbs bound the same conserved epitope located at the VP1 GH loop of EV71. Interestingly, mechanistic studies showed that single antibodies in this MAb group could block EV71 attachment and internalization during the viral entry process and interfere with EV71 binding to heparan sulfate, SCARB2, and PSGL-1 molecules, which are key receptors involved in different steps of EV71 entry. Our findings greatly enhance the understanding of the interplays among EV71, neutralizing antibodies, and host receptors, which in turn should facilitate the development of an MAb-based anti-EV71 therapy.